ScholarIQanswers from OpenAlex & ORCID
Francis P. Worden
ResearcherPublications, citations & collaboration network
Francis P. Worden is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Francis P. Worden have?
ScholarIQindexed works
Francis P. Worden has 549 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Francis P. Worden have?
ScholarIQcitation count
Francis P. Worden has 22,552 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Francis P. Worden?
ScholarIQh-index
Francis P. Worden has an h-index of 64 in OpenAlex.
What is the i10-index of Francis P. Worden?
ScholarIQi10-index
Francis P. Worden has an i10-index of 204 in OpenAlex.
What is the ORCID of Francis P. Worden?
ScholarIQorcid
The ORCID for Francis P. Worden is on the source record.
What is the OpenAlex record for Francis P. Worden?
ScholarIQopenalex
The OpenAlex for Francis P. Worden is on the source record.
What are the most-cited papers on Francis P. Worden?
ScholarIQmost cited works
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, J. Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin J. Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis P. Worden, Nabil F. Saba, Lara Carmen Iglesias Docampo, Robert I. Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Manish Monga, Mark Lynch, William J. Geese, Justin Kopit, James W. Shaw, Maura L. Gillison
Integrative clinical genomics of metastatic cancer
Dan R. Robinson, Yi-Mi Wu, Robert J. Lonigro, Pankaj Vats, Erin F. Cobain, Jessica N. Everett, Xuhong Cao, Erica Rabban, Chandan Kumar‐Sinha, Victoria M. Raymond, Scott M. Schuetze, Ajjai Alva, Javed Siddiqui, Rashmi Chugh, Francis P. Worden, Mark M. Zalupski, Jeffrey W. Innis, Rajen Mody, Scott A. Tomlins, David R. Lucas, Laurence H. Baker, Nithya Ramnath, Ann F. Schott, Daniel F. Hayes, Joseph Vijai, Kenneth Offit, Elena M. Stoffel, J. Scott Roberts, David C. Smith, Lakshmi P. Kunju, Moshe Talpaz, Marcin Cieślik, Arul M. Chinnaiyan
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, J. Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin J. Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis P. Worden, Nabil F. Saba, Lara Carmen Iglesias Docampo, Robert I. Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Mark Lynch, Vijayvel Jayaprakash, Li Li, Maura L. Gillison
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
Lori J. Wirth, Eric J. Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen H. Lorch, Francis P. Worden, Marcia S. Brose, Jyoti D. Patel, Sophie Leboulleux, Yann Godbert, Fabrice Barlési, John C. Morris, Taofeek K. Owonikoko, Daniel S.W. Tan, Oliver Gautschi, Jared Weiss, Christelle de la Fouchardière, Mark E. Burkard, Janessa Laskin, Matthew H. Taylor, Matthias Kroiß, Jacques Médioni, Jonathan W. Goldman, Todd M. Bauer, Benjamin Levy, Viola W. Zhu, Nehal J. Lakhani, Víctor Moreno, Kevin Ebata, Michele Nguyen, Dana Heirich, Edward Y. Zhu, Xin Huang, Luxi Yang, Jennifer Kherani, S. Michael Rothenberg, Alexander Drilon, Vivek Subbiah, Manisha H. Shah, Maria E. Cabanillas
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
Joshua Bauml, Tanguy Y. Seiwert, David G. Pfister, Francis P. Worden, Stephen V. Liu, Jill Gilbert, Nabil F. Saba, Jared Weiss, Lori J. Wirth, Ammar Sukari, Hyunseok Kang, Michael K. Gibson, Erminia Massarelli, Steven Powell, Amy Meister, Xinxin Shu, Jonathan D. Cheng, Robert I. Haddad